The HH signalling pathway A common feature of HH pathway signalling in development is that it acts in close association with several other biological signals; for example, bone morpho genetic proteins (BMPs) 10 , parathyroid hormone 11 and retinoids 12 . Although the pathway has many components and multiple levels of regulation, in most circumstances, it functions in mammals as outlined in FIG. 1. For the most up-to-date, detailed review of HH signalling in metazoans see REF. 13 . In brief, HH ligands bind to Patched (PTCH1), causing internalization and degradation, thereby releasing Smoothened (SMO) to enter the primary cilia where it promotes the dissociation of a Suppressor of fused (SUFU)-glioma-associated oncogene homologue (GLI) complex. This results in nuclear translocation and activation of the GLI1 and GLI2 transcription factors, and degradation of the repressor forms of GLI (primarily GLI3). It is important to keep in mind that the details of these processes have yet to be worked out 14 . Activated GLI proteins stimulate the transcription of HH pathway target genes, including GLI1, GLI2 and PTCH1. As all HH signalling through the canonical pathway requires SMO, small molecules such as cyclopamine, which inhibit SMO function, completely block all HH pathway signalling regardless of the ligand. These agents not only provide valuable tools for dissecting the biochemistry and biology of HH signalling, but they also enabled the development of unique molecularly targeted therapies for cancer.
HH pathway mutations in cancer
The detection of loss-of-function mutations in the HH pathway in familial (Gorlin's syndrome) and sporadic basal cell carcinoma (BCC), as well as medulloblastoma [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , established a clear genetic contribution of HH pathway activity to oncogenesis. Since these initial findings, additional germline and sporadic mutations have been reported in SUFU 26, 27 . Recent studies have also used mutations in the HH pathway to identify the potential cell of origin of BCC and medulloblastoma. The relationships among cancer stem cells, normal stem cells and the cell of origin of specific tumours are often unclear 28 , but given the prominent role HH signalling has in normal development, identifying these cells might prove to be especially informative in tumours that depend on HH pathway activity.
BCC. In the case of BCC, it has been estimated that almost all tumours show evidence of constitutive HH pathway activity, with 90% exhibiting loss of PTCH1 and 10% with activating mutations in SMO 29 . Although the cell of origin of most cancers remains elusive, good candidates have been identified for BCC. Previously, it was suspected that BCC arose from bulge stem cells in the hair follicle 30 . However, targeted expression of an activated Smo gene in mice suggested that long-term resident progenitor cells of the interfollicular epidermis and upper infundibulum gave rise to tumours that resemble BCC 31 .
By contrast, in irradiated Ptch1
+/-mice, BCC was found to arise from keratin 15-expressing stem cells of the follicular bulge 32 . One explanation for the discrepancies in these results is that PTCH1 and SMO have additional distinct functions beyond the HH pathway that also influence tumorigenesis. For example, PTCH1 can sequester cyclin B in the cytoplasm 33 , and this was observed in BCC from Ptch1 +/-mice, but not in mice expressing activated SMO 32 . Furthermore, it seems that loss of p53 promotes BCC formation partly by increasing SMO expression 32 . The effect of p53 loss on SMO expression might also explain why homozygous loss of Trp53 dramatically accelerates medulloblastoma formation in Ptch1 +/-mice, whereas loss of Arf or heterozygous loss of Trp53, neither of which affects the transcriptional function of p53, do not increase tumorigenesis in Ptch1 +/-mice 34 . These findings show that activation of the HH pathway either through the loss of PTCH1 or through the expression of a mutated form of SMO are mechanistically distinct. As pointed out by Wang et al. 32 , although the HH pathway can be activated in cells that do not normally express SMO either by expression of activated SMO or by overexpression of GLI2, loss of PTCH1 in cells that do not express SMO does not achieve the same effect.
The targeted expression of an activated form of GLI2 in stem cell populations in the skin generated a range of tumour phenotypes, depending on the cell of origin and the level of GLI2 expression 35 . This study also showed that it is important to examine the histology of mouse skin tumours carefully as they may represent only a subset of the range of BCC types found in humans. Therefore, we should be cautious when comparing and interpreting data obtained from models that are based on different approaches.
Medulloblastoma.
The situation in medulloblastoma is less uniform, with up to 30% of tumours showing a gene expression signature that is indicative of HH pathway activation, but only 50% of these were associated with loss of PTCH1, loss of SUFU or gain-of-function SMO mutations [36] [37] [38] . Thus, a subset of medulloblastoma exhibits HH pathway activation without evidence of mutations in PTCH1, SMO or SUFU.
Historically, medulloblastoma research was confined to a handful of cell lines and xenografts, although the limitations of such models, including their low predictive value, were well recognized 39 . However, over the past several years, there has been explosive growth in the availability of genetically engineered mouse (GEM) models for brain tumours. In medulloblastoma, most of these models develop as a consequence of HH pathway activation 40 . Mice heterozygous for Ptch1 provide a good model of Gorlin's syndrome, exhibiting several associated phenotypes, including an increased incidence of medulloblastoma (by up to 25%, depending on the genetic background of the mice) [40] [41] [42] [43] . Tumour incidence increases to 100%, and the age of onset is decreased, in the absence of p53 (REF. 34 ). Significant acceleration is also observed following exposure to ionizing radiation 44 . Alterations in genes that function in DNA double-strand break repair and cell cycle control also collaborate with p53 loss to cause medulloblastoma in mice [45] [46] [47] . Mutations in DNA repair genes seem to function by increasing the likelihood of chromosomal alterations in Ptch1 in mouse medulloblastoma 47 , but mutations in DNA repair genes have not been described in human medulloblastoma. Additional mouse models of medulloblastoma have also been created by expressing transgenes with activating point mutations in SMO, which were first identified in BCC 48, 49 , under the control of the Neurod2 promoter 50, 51 . Tumours arising in another mouse model, with heterozygous or homozygous loss of chemokine receptor type 6 (Cxcr6), exhibit an activated HH pathway, and although Ptch1 is not mutated its expression is suppressed 52 . In addition, targeted expression of GLI1, GLI2 or HH ligands can induce
At a glance
• The Hedgehog (HH) pathway is an important regulator of embryogenesis that has also been implicated in tumour development. As all HH signalling through the canonical pathway requires Smoothened (SMO), small molecules such as GDC-0449, which inhibit SMO function, completely block all HH pathway signalling regardless of the ligand.
• Drugs based on cyclopamine and other compounds that target SMO have been developed and are currently in Phase I and Phase II clinical trials. Drugs that target other aspects of the HH signalling pathway are also in development.
• Initial results suggest that SMO inhibitors will prove useful in the treatment of basal cell carcinoma and in the subtype of medulloblastoma that is dependent on HH signalling.
• It is important to understand how HH inhibitors could be used to treat other cancers, perhaps in combination with other therapies, which do not carry genetic lesions in the HH pathway, but that rely on HH signalling for disease progression. Improved understanding of cancer biology, particularly the interplay among cancer cells and stromal tissues, will help broaden the usefulness of such agents.
• The identification of reliable biomarkers that indicate patients who are most likely to benefit from HH inhibitors, including non-invasive imaging approaches, is essential.
• Understanding resistance mechanisms and developing methods to overcome resistance to SMO inhibitors will also be important in the future.
• The importance of HH pathways during development and studies in mice indicate that SMO inhibitors in children with medulloblastoma will need to be used with care, so that potential effects on skeletal and brain development are avoided.
• Given the dramatic responses reported in basal cell carcinoma and medulloblastoma in early trials, it is highly likely that SMO inhibitors will ultimately be approved as new therapeutic agents for treating cancer. This should be viewed as a success for basic, broad-based research in developmental biology, as well as cancer research, which laid a strong foundation for this translational opportunity.
medulloblastoma and tumour formation in the skin [53] [54] [55] . Targeting expression of activated β-catenin to neural precursor cells in mice also results in the development of medulloblastoma, but in this case the WNT pathway is activated in tumours rather than in the HH pathway 56 . At present, the available GEM models do not recapitulate the full genetic diversity of human medulloblastoma, but they do reflect many of the properties of this devastating cancer 40 . These models have made important contributions to our understanding of the aetiology of medulloblastoma and they have provided invaluable tools for proof-of-concept analysis of drugs that target the HH pathway.
Recent studies on the cell of origin of medulloblastoma have identified two potentially different tumour subtypes: those driven by HH pathway mutations and those driven by mutations in the WNT pathway. The origin of HH medulloblastoma was suggested by the close resemblance of gene expression patterns in medulloblastoma cells to those in granule neuron progenitor cells 57 . Genetic studies showed that, although activation of the HH pathway in neural stem cells, as well as granule neuron progenitor cells, results in medulloblastoma formation, stem cells must first make the transition to committed granule neuron progenitors 58, 59 . In this case, it seems that oncogenesis results from the constitutive activation of a signalling pathway, which would normally be active in the cell of origin but which would otherwise be downregulated during the course of development. The WNT molecular subtype of medulloblastoma exhibits a distinct pattern of gene expression and seems to be derived from progenitor cells in the dorsal brainstem in which the HH pathway is inactive 56 . However, the situation might not be so clearcut; as analysis of the medulloblastoma genome recently revealed that some tumours can harbour both HH and WNT pathway mutations simultaneously, indicating that there may be some overlap among the cells of origin 60 .
Rhabdomyosarcoma. Soft tissue tumours that are very similar to human rhabdomyosarcoma (RMS) are seen in Ptch1 +/-mice, but their incidence is strongly influenced by genetic background 61 . Initial descriptions of Gorlin syndrome identified benign fetal rhabdomyoma and rare instances of several other tumours, including RMS 62 . Although it is often stated that RMS is associated with activating mutations in the HH pathway, the role of this pathway in sporadic human RMS is not straightforward.
RMS is a heterogeneous family of tumours, associated with the skeletal muscle lineage, encompassing several distinct molecular and histological subtypes, none of which has been specifically linked to HH pathway mutations 63 . DNA sequence analysis of the PTCH1 coding region from 14 cases of RMS did not reveal any mutations 64 . Although another study reported mutations in PTCH1 and SUFU in RMS, most of the analysis was restricted to loss of heterozygosity (LOH) analysis of PTCH1 and SMO in rhabdomyoma and only one case of RMS 65 . Recently, low level amplification of GLI1 was reported in embryonal RMS, and it was associated with the increased expression of HH pathway target genes 66 . In addition, the comparison of gene expression patterns in human embryonal RMS indicated that approximately 29% exhibited evidence of HH pathway activity, but this was always associated with either p53 or RB pathway signatures 67 . However, the presence of the pathway signature does not necessarily mean that the tumour cells are dependent on SMO activity, as analysis of the effects of cyclopamine on RMS in Ptch1 +/-mice showed that, although loss of PTCH1 may contribute to tumour initiation, it is not required for tumour maintenance 68 .
Other types of cancer with altered HH pathways. Several different molecular lesions in the HH pathway have been described in tumours and, in each case, they resulted in increased transcriptional activity of the GLI1 and GLI2 transcription factors. Indeed, the first indication that genes in the HH pathway were associated with human cancer was the observation that GLI1 was amplified in glioblastoma 69 . Although examples of GLI1 amplification have been described in childhood sarcoma 70 , this does not seem to be a common primary mechanism underlying glioblastoma formation. The location of several other potential oncogenes (including, MDM2 and CDK4) within the same amplicon has complicated the interpretation of these data 71 . Translocations involving GLI1 and ACTB (which encodes β-actin) have defined a new class of pericytoma 72 . Many other tumours lacking HH pathway mutations have been reported to be sensitive to SMO inhibitors in vitro and in vivo 14 . This has led to estimates that up to 25% of human tumours may depend on HH pathway activity for growth 73 and, as a consequence, a broad range of tumours was included in the early clinical trials of SMO inhibitors. Initially, these findings were interpreted to suggest that there was an autocrine feedback loop in some tumours that expressed HH ligands [74] [75] [76] [77] . However, it was subsequently shown in xenograft models that although some human tumours do generate HH ligands, the target genes upregulated by these ligands are expressed in stromal cells of mouse origin 8 . In these cases, treatment with SMO inhibitors slowed tumour growth, but did not eliminate tumours under standard xenograft conditions 8 . In a mouse model of pancreatic cancer, the inhibition of HH signalling enhanced the delivery and response to chemotherapy by depleting tumour-associated stromal tissue 78 . Thus, in addition to targeting tumour cells directly, SMO inhibitors may also show therapeutic benefit through effects on stromal cells. Some leukaemias were also reported to depend on SMO signalling for growth 79, 80 , but this was disputed in subsequent studies on B cell chronic lymphocytic leukaemia, indicating that although GLI1 had an autonomous role in promoting cell survival this role was not dependent on HH ligands or on SMO 81 . The large body of work on the role of SMO signalling in cancer models supports a broader use of SMO inhibitors in tumours other than BCC and a subset of medulloblastoma. The difficulty at present is to identify the tumours that would benefit from treatment, as the presence of HH ligands or a HH pathway signature alone does not guarantee a response.
Targeted therapies for HH pathway tumours
Currently, all of the HH pathway therapeutics in clinical development function by inhibiting SMO (TABLE 1) and thus would be predicted to be ineffective against tumours that harbour molecular lesions that lie downstream of SMO (including, loss of SUFU or gain-of-function mutations in SMO that abrogate the inhibitor-binding site). However, several groups are attempting to develop agents to target GLI that would have a wider application 82 . In addition, arsenic trioxide (ATO) has recently been proposed to directly inhibit GLI proteins by two distinct mechanisms 83, 84 . ATO is thought to block the accumulation of GLI2 in cilia, ultimately resulting in reduced protein levels 83 , and ATO is proposed to bind directly to GLI1, inhibiting its transcriptional function, even in the absence of cilia 84 . As ATO is an approved therapeutic, it may provide an alternative treatment for tumours that develop resistance to SMO inhibitors and could potentially be used in combination therapy with SMO inhibitors.
Preclinical development. Cyclopamine, and other naturally occurring inhibitors of SMO, are not suitable as therapeutic agents because of poor solubility, low potency, rapid clearance, nonspecific toxicity and chemical instability 85 . This encouraged a search for novel inhibitors with preferential characteristics for drug development. HH-mediated GLI transcription activity provided a highly appropriate biomarker for the identification of small-molecule inhibitors, as GLI1 and GLI2 directly contribute to oncogenic activity 55, [86] [87] [88] . Cell-based screening approaches, using GLI-dependent transcriptional reporters, proved remarkably adept at identifying small-molecule inhibitors of SMO 89, 90 . Thus, it seems that SMO is a highly druggable target, and a range of compounds, many with structures distinct from that of cyclopamine, have been uncovered that are capable of binding to the same site to block signalling (reviewed in REF. 91 ). Medicinal chemistry approaches optimized the properties of several 'lead' compounds resulting in a 100-fold increase in potency compared with cyclopamine, as measured in gene expression assays 8, 92, 93 . Preclinical proof-of-concept studies of SMO inhibitors, to establish efficacy in cancer models, have been both challenging and controversial. The advent of GEM models of cancer offered hope that new approaches would be more predictive than the venerable xenograft models. Indeed, a study of acute myeloid leukaemia (AML) allograft transplant models that expressed different translocation fusion genes showed a close concordance to the responses seen in the respective paediatric populations 94 . Nevertheless, the issue remains hotly debated, with strong proponents arguing in favour of xenograft models, others supporting GEM models and some adamant that mouse models of any kind cannot predict clinical outcome.
Most studies of HH pathway activity in cancer have used either human tumour cell lines or xenograft transplantation models treated with cyclopamine to demonstrate dependency on HH pathway activity. Reduced rates of cell proliferation or tumour growth were interpreted to mean that SMO activity was crucial for the growth of the respective tumours 74, 75, 95 . However, different groups have reported contradictory results, even when using the same cell lines or mouse strains carrying identical transplantable tumours 8, [96] [97] [98] [99] [100] . Taken together, several variables in the experimental approaches and the application of the model systems used can account for these discrepancies.
There are no standard approaches to determining whether a particular cell line or tumour depends on HH pathway activity. Therefore, different marker genes have been used to assess pathway activity, and a range of quantitative and semi-quantitative approaches were used to measure gene expression levels, making it problematic to compare results from different studies. Cyclopamine is toxic 85 and can cause growth inhibition independently of HH pathway activity when used at high concentrations, depending on the cell type 8, 101 . This means that it is important to use cyclopamine at a concentration that inhibits the HH pathway but that does not cause nonspecific growth inhibition. This is difficult because there is no agreed standard method to measure HH pathway activity. As a consequence, although some studies report that concentrations of cyclopamine of 3 μM and above can result in nonspecific growth inhibition 8, 101 , others
Box 1 | HH pathway in development
The Hedgehog (HH) pathway was identified in Drosophila melanogaster 121 , where it was ultimately shown to control segmental pattern formation. In mammals, three genes, Desert Hedgehog (DHH), Indian Hedgehog (IHH) and Sonic Hedgehog (SHH), function as ligands for Patched (PTCH1) in a wide range of developmental signalling roles 122 . In some cases, HH ligands clearly function as mitogens, whereas in others they promote differentiation 13 . The importance of HH signalling in mammalian development is underscored by observations that mutations in SHH cause holoprosencephaly (HPE) [123] [124] [125] . HPE is a developmental disorder that affects the midline of the face and nervous system. It is characterized by cleft lip and palate, a single central incisor, impaired central nervous system septation and in severe cases complete cyclopia. A similar constellation of phenotypes has long been associated with the exposure of developing embryos to naturally occurring teratogenic alkaloids such as cyclopamine 126 . Indeed, the presence of these teratogens in extracts from Veratrum Album, which is commonly known as White Hellebore and is part of Liliaceae (the lily family), that were used in ancient medicine, may have provided a source for the legendary Cyclops 127 . Initially, the mechanism responsible for these effects was thought to relate to the ability of these compounds to inhibit cholesterol biosynthesis; however, it was subsequently demonstrated that they function as specific inhibitors of HH signalling 128, 129 by binding to SMO 130 . Thus, both the importance of the HH pathway in regulating growth, and the identification of a potential inhibitor, had their origins in developmental biology research.
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claim that cyclopamine can function as a specific HH pathway inhibitor at levels of up to 30 μM 100 . Although several studies used complementary genetic approaches, such as small interfering RNAs to inhibit GLI1 or GLI2, as independent confirmation of the effects of cyclopamine, this approach does not demonstrate HH dependence on SMO. For example, GLI1 and GLI2 have been shown to function independently of HH pathway activity and SMO in B cell chronic lymphocytic leukaemia 81 . Therefore, the fact that GLI1 and GLI2 are required for tumour cell viability does not necessarily mean that SMO is active in these cells and therefore does not confirm the effects of cyclopamine. In vivo, it is difficult to reach systemic levels of cyclopamine that completely inhibit HH pathway activity because of its associated toxicities 85, 101 . Thus, it is likely that the role of HH pathway activity in human cancer has been overestimated as a consequence of the prevalent use of cyclopamine at toxic concentrations.
In many cases, alternative routes of administration were used to deliver cyclopamine. For example, in some instances cyclopamine was delivered by subcutaneous inoculation 95, 96 . This often caused ulceration at the injection site, as the vehicle contained alcohol. This route is not directly comparable to systemic delivery and it is not clear whether it resulted in the same amount of the drug being delivered to the tumour cells. When the route of administration was changed to oral delivery, it was not possible to achieve the same degree of tumour inhibition 102 . In most cases the level of cyclopamine achieved in tumour tissues was not determined; however, subcutaneous inoculation may have resulted in greater bioavailability, increased levels of exposure and higher specific, as well as nonspecific, toxic effects.
Studies in which cyclopamine was injected directly into the tumour mass are of much greater concern 103 . In some studies, the administration route was described as both proximal and direct into the tumour mass 104, 105 . In these cases, the actual concentration of cyclopamine to which tumour cells are exposed is extremely high and would probably result in nonspecific toxicity. Finally, although the standard xenograft approach recommends treating tumours only after they are fully established as transplants (with a volume of approximately 200-400 mm 3 ) some studies used much smaller tumours, even as small as 10 mm 3 , before the tumours were fully established 105 . Thus, a series of methodological differences in preclinical experimental design, combined with the high degree of nonspecific toxicity that is associated with cyclopamine, may account for some of the conflicting findings that have been reported in the literature. These reports may have considerably overstated the potential of SMO inhibitors for treating human cancer.
Compounding these problems is the fact that pharma ceutical companies generally decline to supply compounds that are currently in development for such studies, because of fears that negative results would compromise the approval process. Therefore, most investigators relied on the use of cyclopamine, despite reservations about its properties, to test the contribution of SMO to tumour growth in vitro and in vivo. The notable exception was a set of compounds identified by Curis, and subsequently developed in collaboration with Genentech, that were used to show the efficacy of SMO inhibitors in BCC explant cultures 29, 106 and in mouse models of medulloblastoma 52, 101 . One particular compound, a benzimidazole termed HhAntag, provided the most compelling preclinical data on the efficacy of SMO inhibitors. Oral delivery of HhAntag eradicated large medulloblastomas that arise spontaneously in the cerebellum of Ptch1 +/-;Trp53 -/-mice 101 . However, tumour cell lines derived from these medulloblastomas, as well as allograft tumours made using these cell lines, were completely resistant to the inhibitory effects of HhAntag because the HH pathway was dramatically downregulated as soon as these cells were propagated in culture. By contrast, allografts that were derived directly from the medulloblastomas that had never been grown in culture exhibited dramatic sensitivity, with large tumour masses (200 mm 3 ) regressing after only 4 days of treatment 52 . These model studies predicted that BCC and the HH pathway subtype of medulloblastoma would exhibit substantial responses to SMO inhibitors in the clinic and led to the inclusion of patients with medulloblastoma in the initial clinical trials.
Clinical trials.
The results of the first Phase I trial of the SMO inhibitor GDC-0449 reported that 19 of 33 patients with BCC, and one patient with medullo blastoma, exhibited either a partial or a complete response to this novel therapy 6 . An unprecedented 50% response rate was observed in patients with metastatic BCC 3, 6 . A dramatic, albeit transient, response was also reported in an adult with metastatic medulloblastoma 4 , and encouraging results in a Phase I paediatric medulloblastoma clinical trial were reported at the 2010 American Society of Clinical Oncology meeting 107 , Figure 1 | Summary of the HH signalling pathway. Hedgehog (HH) ligands bind to Patched (PTCH1), causing internalization and degradation, and the release of the suppression of Smoothened (SMO) by PTCH1. SMO enters the primary cilia where it is activated (shown by dashed arrow). SMO then interacts with Suppressor of fused (SUFU), which, in turn, promotes the activation and nuclear translocation of glioma-associated oncogene homologue 1 (GLI1) and GLI2 and the degradation of GLI3.
Acrocapitofemoral dysplasia
An autosomal recessive disorder caused by hypomorphic mutations in Indian Hedgehog (IHH) that is associated with cone-shaped epiphyses in hands and hips.
suggesting that the preclinical data on BCC and medulloblastoma were indicative of a response. In the one case of metastatic adult medulloblastoma, the patient subsequently relapsed because of mutation of the drug-binding site in SMO 2 . This unfortunate circumstance provided strong affirmation of SMO as a drug target and echoed early experiences with Imatinib (Gleevec; Novartis), which was the prototypical molecularly targeted therapy 108 . Resistance to inhibitors also readily arises in animal models as a consequence of mutations in Smo, amplification of Gli2 or amplification of Ccnd1 (which encodes cyclin D1) 2, 109, 110 . It is likely that drug resistance will be an important aspect of clinical treatment with HH pathway inhibitors, and compounds have already been identified that can overcome resistance that results from SMO mutations 110 . However, this approach will not be successful in resistant tumours that acquire mutations downstream of SMO. Some hope has been offered by the recent finding that blocking PI3K activity inhibits the growth of certain resistant tumours 109 . In contrast to the dramatic clinical results reported in early studies on patients with BCC or medulloblastoma, no major responses to SMO inhibitors have yet been reported in other cancers 6 . Although Phase I trials are designed to test drug safety, not efficacy, the positive effects on BCC and medulloblastoma were very obvious. In addition, two trials of GDC-0449 have been closed to patient accrual (Trial numbers NCT00739661 and NTC00636610; see ClinicalTrials.gov). In the case of advanced ovarian cancer, GDC-0449 was being used in a maintenance setting as a single agent in a Phase II clinical trial, but it did not sufficiently extend the median time to recurrence. In the case of colon carcinoma, a Phase II combination therapy clinical trial of GDC-0449 plus bevacizumab (Avastin; Genentech/Roche) failed because treatment did not extend the time from randomization to disease progression or death. A major caveat in the interpretation of the results of the initial clinical trials is that patients were not selected on the basis of the presence of HH pathway activity in tumour tissue (BOX 2) . Previous experience with protein kinase inhibitors showed that therapeutic effects are often not detected without the molecular stratification of patients. It is important to learn from these experiences by including tests that determine the suitability of patient populations for treatment with HH pathway inhibitors, as well as assays for monitoring the effect of treatment on the target at all stages of the drug development process 111 . Currently, seven compounds that bind and inhibit SMO are listed for use in a range of advanced cancers in more than 40 different clinical trials (TABLE 1) . The most widely used compound is the first-in-class Vismodegib (GDC-0449), which was developed by Curis and Genentech 6, 92, 112 . In mammals, HH pathway activity depends on the primary cilia 113 . HH binding to PTCH1 allows SMO to translocate to the ciliary membrane where it relieves repression of GLI1 and GLI2 by SUFU. Although cyclopamine binding to SMO promotes trans location to the primary cilia through the intraflagellar transport pathway, it does not activate GLI1 or GLI2 (REFS 114, 115) . By contrast, the antagonists SANT1 and SANT2, which bind to the same site on SMO, do not promote cilial translocation of SMO 114, 115 . These findings imply that SMO has multiple conformations that could be exploited for drug development. Future research on the mechanisms responsible for SMO function and the downstream events leading to GLI activation will be particularly important if gain-of-function mutations in SMO occur frequently in drug-resistant tumours. At present, it is not clear which of the many SMO inhibitors currently in drug development would be least affected by acquired mutations in SMO.
Side effects. SMO inhibitors have exhibited remarkably few and fairly modest side effects in adult patients 6 (TABLE 2) . However, when given to young mice for as little as 2-4 days HhAntag caused dramatic and permanent defects in bone growth 116 . Short-term treatment of 10-day-old mice resulted in malformation of the epiphysis and growth plate. The columnar organization of chondrocytes in the growth plate was disrupted, and the cartilage structure appeared dysplastic. These observations are consistent with the crucial role that the HH pathway is known to have in bone development 117 . Deletion of Indian Hedgehog (Ihh) causes embryonic lethality in mice 118 ; conditional ablation results in a phenotype similar to that seen in mice treated with HhAntag
119
; and hypomorphic mutations of IHH in humans cause acrocapitofemoral dysplasia 120 . The several roles that HH signalling has in development, including the postnatal formation of the cerebellum 58, 59 , raise many concerns about potential side effects that may be seen in the youngest patients (TABLE 2) .
Conclusions and perspectives
Given the dramatic responses reported in BCC and medulloblastoma in early clinical trials 6 , it is highly likely that SMO inhibitors will ultimately be approved as new therapeutic agents for treating cancer. This should be
Box 2 | Personalizing HH-based therapies
One of the major challenges in the use of Smoothened (SMO) inhibitors for treating cancer is how to identify the tumours that are capable of responding. Although genetic testing can reveal the presence of Patched (PTCH1) mutations, this would only identify a subset of susceptible cases. Biomarkers for Hedgehog (HH) pathway activity can be used, but this also identifies tumours with activating mutations in SMO, as well as those with lesions downstream of SMO, that would be resistant to treatment. Currently, RNA expression signatures are used as the primary biomarker, as there are no antibodies specific for HH pathway target genes that work reliably in immunohistochemistry assays 30 . However, additional biomarkers were recently proposed that could discriminate between medulloblastoma subsets 131, 132 . In the case of advanced basal cell carcinoma (BCC), molecular diagnostics is not a major issue as most tumours exhibit an activated HH pathway. However, it is a concern for medulloblastoma, in which only 30% of tumours have an activated HH pathway and only 50% of these have PTCH1 mutations. In addition, different biomarkers will be needed to identify tumours in which HH signalling functions through stromal cells, as the presence of HH ligands in these tumours is also not sufficient to predict responses 8 . The lack of appropriate biomarkers makes it challenging to develop robust criteria for the stratification of patients with tumours other than BCC or medulloblastoma for treatment with SMO inhibitors. Therefore, it is important to revisit preclinical studies of SMO inhibitors in both genetic and xenograft models of these other tumours, to understand the mechanism of action and to develop diagnostic markers.
viewed as a success for basic, broad-based research in developmental biology, as well as for cancer research, which laid a strong foundation for this translational opportunity. Credit should also be given to the many useful partnerships among investigators working in academia, biotechnology companies and in the pharmaceutical industry that brought these projects to fruition. However, there are many challenges ahead that illustrate common hurdles that are likely to be faced during the development of other molecularly targeted therapies for the treatment of cancer.
One major issue is that if SMO inhibitors were only effective in advanced BCC and a subset of medulloblastoma, the number of patients that could benefit from treatment would not provide an adequate return on investment from an economic perspective. Therefore, it is important to understand how these inhibitors could be used to treat other cancers that do not carry genetic lesions in the HH pathway, perhaps in combination with other therapies. Similar problems may be encountered with other targeted therapies, as genomic research continues to subdivide cancers into increasingly smaller molecular subtypes. It is hoped that by understanding the mechanisms of action, and by proving the efficacy of novel, specific agents in rare genetically defined cancers, we will also learn how to treat the more prevalent forms of cancer. Clearly, improved understanding of cancer biology, particularly the interplay among cancer cells and stromal tissues, will help to broaden the usefulness of such agents. The identification of reliable biomarkers, including noninvasive imaging approaches, will also be very important for selecting the patients who would benefit from treatment and for monitoring responses to therapy.
Understanding resistance mechanisms and developing methods to overcome resistance to SMO inhibitors will also be important in the future. Currently, the patients being treated with SMO inhibitors in clinical trials have advanced disease, so they have already been treated with chemotherapy and in many cases radiation therapy. These mutagenic treatments increase the likelihood of developing resistance. In the case of BCC, early treatment, by surgical removal of lesions, is curative in the vast majority of cases. Therefore, it will be important to determine the circumstances in which treatment with a SMO inhibitor would be preferred over the surgical approach. In medulloblastoma, surgery is usually scheduled as soon as possible after diagnosis and is often followed with radiation and chemotherapy treatment. However, in the future it may be possible to identify and treat the HH pathway subtype of medulloblastoma with SMO inhibitors before these other interventions that, although often successful, can result in substantial morbidity. 
